Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H2 2017

Published: Sep, 2017 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H2 2017

Summary

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Coagulation Factor XI - Pipeline Review, H2 2017, outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor.  The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 5 and 6 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders and Infectious Disease which include indications Thrombosis, Bleeding And Clotting Disorders, Arterial Thrombosis, Sepsis, Venous (Vein) Thrombosis, Venous Thromboembolism, Acute Ischemic Stroke, Bacterial Sepsis, Hemophilia C (Factor XI Deficiency), Ischemic Stroke and Stroke. 

Furthermore, this report also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
- The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Overview 7
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Assessment 15
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Companies Involved in Therapeutics Development 21
Bayer AG 21
Bristol-Myers Squibb Co 21
Ionis Pharmaceuticals Inc 22
Mochida Pharmaceutical Co Ltd 22
Novartis AG 23
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Drug Profiles 24
AB-012 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
AB-022 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
BAY-1213790 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
BMS-262084 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
BMS-654457 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
BMS-962212 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
coagulation factor XI (human) - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
coagulation factor XI (human) - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
EP-7041 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
IONIS-FXILRx - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
IONIS-FXIRx - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Ir-CPI - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
MAA-868 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
MR-1007 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Inhibit Factor XIa for Cardiovascular - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Products 43
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Product Development Milestones 44
Featured News & Press Releases 44
Jul 03, 2017: Bayer To Present Data on BAY 1213790 at ISTH 2017 44
Nov 01, 2016: Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis 44
Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis 45
Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022 46
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 46
Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 47
May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 48
May 22, 2014: Cambryn Biologics Receives From FDA Orphan Drug Designation For Human Factor XI 48
Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma 49
Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery 49
Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding 50
Feb 02, 2011: Isis Initiates Phase I Clinical Trial Of ISIS-FXIRx To Treat Clotting Disorders 51
Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 12
Number of Products under Investigation by Universities/Institutes, H2 2017 13
Products under Investigation by Universities/Institutes, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 16
Number of Products by Stage and Route of Administration, H2 2017 18
Number of Products by Stage and Molecule Type, H2 2017 20
Pipeline by Bayer AG, H2 2017 21
Pipeline by Bristol-Myers Squibb Co, H2 2017 22
Pipeline by Ionis Pharmaceuticals Inc, H2 2017 22
Pipeline by Mochida Pharmaceutical Co Ltd, H2 2017 23
Pipeline by Novartis AG, H2 2017 23
Dormant Projects, H2 2017 43